BMS and 2seventy bio’s Abecma approved for multiple myeloma
Share this article Abecma will now be available for r/r MM patients who previously received two or more lines of treatment. Credit: Bristol Myers Squibb
Share this article Abecma will now be available for r/r MM patients who previously received two or more lines of treatment. Credit: Bristol Myers Squibb
The FDA approved the first test that uses DNA to identify whether adults have an elevated risk of developing opioid use disorder (OUD), the agency
Tim Quinlan, Sr. Technical Manager at Coder It’s no surprise that one of healthcare leaders’ biggest fears is having customer data stolen, leaked or exposed.